Encompass Health
EHC
$106.70
-0.80%
Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States, operating a national network of inpatient rehabilitation hospitals. The company is a pure-play market leader in the inpatient rehabilitation facility (IRF) segment, specializing in rehabilitative care for patients recovering from strokes, neurological disorders, cardiac conditions, and complex orthopedic surgeries. The current investor narrative centers on the company's ability to navigate a challenging labor and reimbursement environment while demonstrating resilient organic growth and operational execution, as evidenced by its consistent dividend declarations and focus on shareholder returns.…
EHC
Encompass Health
$106.70
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating & Thesis: Hold. EHC is a fundamentally sound company caught in a negative momentum cycle, making it a 'show me' story where the valuation is attractive but requires a catalyst to reverse sentiment. The consensus among the few covering analysts is bullish (Buy/Overweight), but the stock price has not reflected this optimism.
Supporting Evidence: The stock trades at a forward PE of 16.56x, which is below its own trailing multiple of 18.84x and suggests the market expects modest growth. The PEG ratio of 0.78 signals potential undervaluation relative to growth. Revenue growth remains healthy at 9.94% YoY, and profitability is robust with a 23.22% ROE. Strong free cash flow generation ($439M TTM) supports the dividend (0.67% yield) and provides financial flexibility. However, these positives are offset by the stock's -24.51% relative underperformance versus the market over the past year.
Risks & Conditions: The two biggest risks are 1) a failure to break the technical downtrend, leading to a retest of the $92.77 low, and 2) a deceleration in revenue growth below 8% YoY, which could further compress the PE multiple. This Hold rating would upgrade to a Buy if the stock sustains a breakout above the $113.43 resistance level on strong volume, signaling a trend reversal, or if quarterly revenue growth re-accelerates above 11% while margins hold. It would downgrade to a Sell if revenue growth decelerates below 6% or if net margins contract below 8%. The stock appears fairly valued to slightly undervalued relative to its own growth profile but remains overvalued in the eyes of momentum-driven market participants.
Sign up to view all
EHC 12-Month Price Forecast
EHC presents a dichotomy of attractive fundamentals and poor price momentum. The valuation (PEG 0.78, forward PE 16.56x) is compelling for a company with a 23% ROE and nearly 10% revenue growth. However, the stock's persistent underperformance and technical downtrend cannot be ignored, reflecting legitimate market concerns about future growth and margin sustainability. The base case of range-bound trading is most likely, as the company's defensive cash flows provide a floor, but a lack of explosive growth catalysts limits upside. The stance would upgrade to Bullish on a confirmed technical breakout above $113.43 coupled with evidence of margin stability. It would downgrade to Bearish if revenue growth decelerates below 7% or if the stock breaks below the $97 support level established in March 2026.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $138.71 and implied upside of +30.0% versus the current price.
Average Target
$138.71
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$85 - $139
Analyst target range
Analyst coverage for EHC is limited, with only 3 analysts providing estimates, which is typical for a mid-cap healthcare services company and can lead to higher volatility and less efficient price discovery. The available data points to a consensus that is implicitly bullish, with institutional ratings from firms like Barclays, UBS, and BofA Securities consistently maintaining 'Buy' or 'Overweight' equivalents throughout 2025 and into early 2026, indicating sustained positive sentiment among the covering firms. The target price range implied by EPS estimates is narrow; the average estimated EPS for the coming year is $7.69, with a low of $7.65 and a high of $7.76. This tight range suggests strong analyst conviction in the company's earnings power, though the lack of explicit price targets limits the calculation of implied upside. The pattern of recent institutional ratings shows no downgrades, only reiterations of positive ratings, which reinforces a stable, constructive outlook from the Street despite the stock's price weakness.
Bulls vs Bears: EHC Investment Factors
The evidence presents a classic battle between value and momentum. The bull case is grounded in strong fundamentals: robust profitability, healthy cash flow, a compelling PEG ratio suggesting undervaluation, and resilient revenue growth. The bear case is driven by powerful technicals and sentiment: severe long-term underperformance, valuation multiple compression, and a clear downtrend. Currently, the bearish momentum and sentiment appear stronger, as reflected in the stock's price action. The single most important tension is whether the company's solid fundamental performance (9.94% YoY revenue growth, 23% ROE) can overcome the market's negative momentum narrative and trigger a re-rating of its compressed valuation multiples.
Bullish
- Strong Profitability & Cash Flow: The company maintains robust profitability with a Q4 net margin of 9.46% and a trailing ROE of 23.22%. It generates substantial free cash flow ($439.2M TTM), providing a solid foundation for dividends and share buybacks.
- Undervalued Growth (PEG 0.78): A PEG ratio of 0.78, based on trailing metrics, suggests the stock is undervalued relative to its earnings growth rate. This is a classic value signal, indicating the market may not be fully pricing in future growth.
- Resilient Revenue Growth: Q4 2025 revenue grew 9.94% YoY to $1.54B, re-accelerating from earlier quarters. This demonstrates resilient underlying demand for post-acute care services despite a challenging macro environment.
- Defensive Profile & High Short Interest: A beta of 0.6 makes EHC 40% less volatile than the market, a defensive characteristic. A short ratio of 4.19 indicates significant bearish positioning, which could fuel a short squeeze on any positive fundamental catalyst.
Bearish
- Severe Long-Term Underperformance: The stock has a -24.51% 1-year relative strength vs. the S&P 500 and is down -12.20% over six months. This persistent underperformance reflects deep-seated market skepticism about its growth narrative.
- Valuation Compression from Highs: The trailing PE has compressed from 25.23x in Q3 2025 to 18.84x currently. This multiple contraction signals the market has significantly lowered its growth and/or margin expectations for the company.
- Limited Analyst Coverage & Price Discovery: Only 3 analysts provide estimates, which is low for a $10.7B market cap company. This can lead to less efficient price discovery, higher volatility, and a greater risk of mispricing due to limited scrutiny.
- Moderate Financial Leverage: A debt-to-equity ratio of 1.11 indicates a moderate level of leverage. In a rising interest rate environment, this could pressure net income through higher interest expenses, as seen in recent quarters.
EHC Technical Analysis
The stock is in a pronounced downtrend over the past six months, with a price decline of -12.20% from the highs observed in October 2025. Currently trading at $107.25, the price sits at approximately 83.8% of its 52-week range ($92.77 to $127.99), indicating it is closer to the lower bound, which may present a potential value opportunity but also reflects significant selling pressure and negative momentum relative to the broader market. Recent momentum shows a notable divergence, with the stock gaining 6.58% over the past month, sharply contrasting with its negative 1-year relative strength of -24.51% against the S&P 500. This positive 1-month move, coupled with a 4.20% gain over the past three months, suggests a potential near-term recovery or oversold bounce, though it remains to be seen if this can reverse the longer-term underperformance. Key technical levels are clearly defined, with immediate support at the 52-week low of $92.77 and resistance at the 52-week high of $127.99. A sustained breakout above the recent recovery high near $113.43 would be needed to signal a more durable trend reversal. The stock's beta of 0.6 indicates it is 40% less volatile than the market, which, combined with a high short ratio of 4.19, suggests it is a lower-risk, defensive name that is also heavily shorted, potentially setting the stage for a short squeeze if positive catalysts emerge.
Beta
0.60
0.60x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
+3.3%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | +6.3% | +4.9% |
| 3m | +6.5% | +0.6% |
| 6m | -13.3% | +5.1% |
| 1y | +3.3% | +28.8% |
| ytd | +0.3% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Revenue growth remains healthy but has shown some sequential deceleration; Q4 2025 revenue was $1.5446 billion, representing a solid 9.94% year-over-year increase. However, examining the quarterly progression within 2025 reveals a pattern: Q1 revenue was $1.4554B, Q2 $1.4577B, Q3 $1.4775B, and Q4 $1.5446B, indicating growth re-accelerated in the final quarter, which is a positive sign for the underlying demand trajectory. The company is consistently profitable, with Q4 2025 net income of $146.1 million and a net margin of 9.46%. Profitability metrics are robust, with a gross margin of 22.78% for the quarter and an operating margin of 17.74% (based on valuation data). Margins have demonstrated stability; the quarterly net margin has fluctuated between 8.56% and 10.41% through 2025, showing the company's ability to maintain profitability despite cost pressures. The balance sheet and cash flow generation support financial health, with a debt-to-equity ratio of 1.11, indicating a moderate but manageable level of leverage. The company generates substantial cash, with trailing twelve-month free cash flow of $439.2 million and an operating cash flow of $346 million for Q4 2025 alone. This strong cash generation, evidenced by a current ratio of 1.08 and a return on equity of 23.22%, provides ample liquidity to fund operations, service debt, and return capital to shareholders through dividends and share repurchases.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.22%
Latest Quarter
Free Cash Flow
$439199999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Given the consistent positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 18.84x, while the forward PE is lower at 16.56x, indicating the market anticipates earnings growth, with the forward multiple pricing in an expected EPS of approximately $7.69 for the coming year. Compared to sector averages, the stock's valuation presents a mixed picture; its forward PE of 16.56x is not directly comparable without a provided industry average, but its Price-to-Sales ratio of 1.80x and EV/EBITDA of 9.46x suggest a reasonable valuation for a stable healthcare services company. The PEG ratio of 0.78, based on trailing metrics, implies the stock may be undervalued relative to its growth rate, as a figure below 1.0 typically suggests the market is not fully pricing in future growth prospects. Historically, the stock's own valuation has compressed; its current trailing PE of 18.84x is below the higher end of its recent historical range observed in Q3 2025 (25.23x) and is more in line with its levels from early 2024. Trading near the middle-to-lower end of its own historical PE band suggests the market's expectations have been reset lower, potentially limiting downside risk if fundamentals remain stable, but also reflecting diminished growth optimism.
PE
18.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 14x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EHC's primary financial risk is its moderate leverage, with a debt-to-equity ratio of 1.11. While manageable, this exposes the company to interest rate risk, as evidenced by a $30.2M interest expense in Q4 2025. Operational risks center on margin pressure; although net margins are stable (8.56%-10.41% in 2025), the healthcare sector faces persistent labor cost inflation and potential reimbursement rate pressures from government payors like Medicare, which could compress the 17.74% operating margin. The company's revenue is concentrated in a single segment (inpatient rehabilitation), leaving it exposed to sector-specific regulatory changes.
Market & Competitive Risks: The key market risk is valuation compression, as the stock's forward PE of 16.56x, while reasonable, has already fallen from recent highs. If growth decelerates or sector multiples contract further, the stock could re-rate lower. Competitive risks stem from other post-acute providers and potential shifts in patient discharge patterns from acute-care hospitals. The stock's low beta (0.6) offers defensive characteristics but also means it may not participate fully in market rallies. The high short ratio (4.19) is a double-edged sword, representing both a potential squeeze catalyst and significant bearish sentiment that must be overcome.
Worst-Case Scenario: A worst-case scenario involves a combination of a severe economic downturn reducing elective procedures, coupled with unfavorable Medicare reimbursement changes and a spike in labor costs. This could trigger an earnings miss, leading to analyst downgrades and a flight from the stock. In this adverse scenario, the price could realistically revisit its 52-week low of $92.77, representing a downside of approximately -13.5% from the current $107.25. A more severe drawdown could approach the -26.22% maximum drawdown observed in the data, implying a potential loss in the -25% to -30% range if sentiment turns deeply negative.
FAQ
The key risks are: 1) Momentum & Sentiment Risk: The stock has severe negative momentum (-24.51% relative strength) which can become self-fulfilling. 2) Regulatory & Reimbursement Risk: As a healthcare provider, revenues are heavily influenced by government (Medicare/Medicaid) payment rates, which are subject to political and budgetary pressures. 3) Operational Risk: The business faces persistent cost pressures, particularly from labor inflation, which could compress the 17.74% operating margin. 4) Financial Risk: A debt-to-equity ratio of 1.11 introduces leverage, though it is currently manageable. The momentum and regulatory risks are currently the most severe, as they drive the negative sentiment overshadowing strong fundamentals.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $107 and $117, as steady execution meets modest expectations without a major catalyst. The Bull Case (25% probability) targets $120 to $128, driven by an earnings beat, positive industry news, and a short squeeze. The Bear Case (15% probability) warns of a drop to $93-$100 if operational pressures mount and support levels break. The base case is most likely, anchored by analyst EPS estimates of $7.69 and the stock's current valuation multiples. The key assumption is that revenue growth remains stable in the high-single-digit range.
Based on fundamentals, EHC appears slightly undervalued. The primary metric is the PEG ratio of 0.78 (trailing), which is below 1.0 and typically indicates the market is not fully pricing in growth. Its forward PE of 16.56x is also below its trailing PE of 18.84x, suggesting expectations are modest. Compared to its own history, the stock trades at the lower end of its recent PE range, having compressed from over 25x. The market is paying a fair-to-discounted price for steady growth and high profitability, but it is demanding a discount due to sector headwinds and poor momentum. The valuation implies the market expects mid-single-digit earnings growth, which may be too conservative.
EHC is a good buy for value-oriented, patient investors who can tolerate near-term volatility. The stock offers a compelling PEG ratio of 0.78 and a forward PE of 16.56x for a company growing revenue at nearly 10% with a 23% ROE. The implied upside is tied to a potential re-rating if fundamentals overcome negative sentiment. However, it is not a good buy for momentum traders, as the stock has significantly underperformed the market (-24.51% over one year). The biggest downside risk is a break below the $92.77 support level. It is a good buy under the condition that an investor believes the company's solid cash flows will eventually be rewarded by the market.
EHC is far more suitable for a long-term investment horizon (2+ years) than for short-term trading. Its low beta (0.6) and dividend provide defensive characteristics for a portfolio, but the stock's negative momentum and lack of near-term catalysts make it a poor short-term trade. A long-term horizon allows time for the company's fundamental strengths—strong cash flow, market leadership, and essential services—to be recognized and for any potential multiple expansion to occur. The stock's volatility, evidenced by a 26.22% max drawdown, also argues against short-term holding. A minimum holding period of 12-18 months is suggested to weather potential volatility and allow the investment thesis to play out.
